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Abstract
Background: Chronic cough is common and is associated with significant economic and human costs. While
cough can be a problematic symptom without serious consequences, it could also reflect a serious underlying
illness. Evidence shows that the management of chronic cough in children needs to be improved. Our study tests
the hypothesis that the management of chronic cough in children with an evidence-based management pathway
is feasible and reliable, and improves clinical outcomes.
Methods/Design: We are conducting a multicentre randomised controlled trial based in respiratory clinics in
5 major Australian cities. Children (n = 250) fulfilling inclusion criteria (new patients with chronic cough) are
randomised (allocation concealed) to the standardised clinical management pathway (specialist starts clinical
pathway within 2 weeks) or usual care (existing care until review by specialist at 6 weeks). Cough diary, cough-
specific quality of life (QOL) and generic QOL are collected at baseline and at 6, 10, 14, 26, and 52 weeks. Children
are followed-up for 6 months after diagnosis and cough resolution (with at least monthly contact from study
nurses). A random sample from each site will be independently examined to determine adherence to the pathway.
Primary outcomes are group differences in QOL and proportion of children that are cough free at week 6.
Discussion: The clinical management pathway is based on data from Cochrane Reviews combined with collective
clinical experience (250 doctor years). This study will provide additional evidence on the optimal management of
chronic cough in children.
Trial registration: ACTRN12607000526471.
Background
Cough is the most common symptom presenting to
primary care in Australia and internationally [1,2]. It is one
of the most common reasons for referral to respiratory
physicians. The burden of the symptom is considerable-
both in terms of personal cost (e.g. impaired quality of life
and multiple doctor consultations) [3] and at a societal
level (through absences from school and work [4,5] and
substantial medication expenses) [6]. Our previous studies
have shown that >80% of parents of children with chronic
cough have sought ≥5 medical consultations prior to refer-
ral [3]. Furthermore, ignoring cough (which may be the
sole presenting symptom of an underlying respiratory
illness) could lead to progression of a serious illness (such
as bronchiectasis or retained foreign body in the airways)
[7,8]. Paradoxically, cough is poorly researched. Patients
are often inappropriately investigated and managed [9].
The need to improve the management of chronic cough in
children is reflected in international [10-12] and Australian
data [4,9], and our own collective experience.
The use of guidelines, recommendations, and clinical
pathways can improve the quality of care [13,14]. Suc-
cessful development of clinical guidelines requires many
strategies. Initially, endorsement from experts and high
quality of the evidence are important [15]. However, the
use of guidelines is not universally popular in medical
circles. “Numerous clinicians consider the compliance
with tightened standards of care an impediment to their
therapeutic freedom by imposing ‘cookbook medicine’
as a dogma” [14]. Also, provision of guidelines alone are
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the case for changing practice to be consistent with
guidelines is much greater when the guidelines have
been shown to improve patient outcomes. While multi-
ple cough pathways exist, none has been subjected to a
randomised controlled study [16]. Currently, the poten-
tial benefit of this type of management remains unclear.
In our study, we will evaluate the feasibility and effec-
tiveness of an evidenced-based clinical management
pathway.
Aims of the study
Our primary question in conducting the study is:
Among Indigenous and non-Indigenous children with
chronic cough, does management according to a stan-
dardised clinical management pathway (compared to
usual treatment) improve clinical outcomes by 6 weeks?
Our secondary aims are to:
1. Assess the reliability and validity of a standardised
clinical management pathway for chronic cough in chil-
dren; and
2. Compare the outcomes of chronic cough in Indi-
genous children with non-Indigenous children.
Our hypothesis is: The management of chronic cough
in children in accordance with a evidence-based man-
agement pathway is feasible, reliable and improves clini-
cal outcomes.
Methods/Design
Study design
We are conducting a pragmatic multi-centre rando-
mised controlled trial (RCT) in urban respiratory specia-
list clinics in 5 major Australian centres: Brisbane,
Melbourne, Sydney, Canberra and Darwin.
Eligibility
Inclusion criteria: Children aged <18 years with chronic
cough (>4 weeks duration)referred to a respiratory spe-
cialist for the first time. Exclusion criteria: Children with
a known chronic respiratory illness previously diagnosed
by a respiratory physician (eg cystic fibrosis).
Recruitment
At each site, all referrals are screened by the site-specific
study nurse. Parents are informed of the usual waiting
times (6-8 weeks) and invited to participate. After
informed consent, participants are randomised to either
the active or control arms.
Intervention and follow up
Children in the active arm enter the clinical pathway
within 2 weeks of consent. They are managed according
to the clinical pathway for at least 4 weeks before reas-
sessment at 6 weeks (primary outcome). Children in the
control arm enter the pathway at the usual waiting time
(6 to 8 weeks). Since all of the participating clinics
usually have a waiting time of at least 6 weeks, the con-
trol arm essentially represents usual practice. The
enrolled child is managed according to the clinical path-
way (figures 1 and 2). Each child is followed clinically
until a primary diagnosis and cough resolution are
achieved (max 12 months). Following cough resolution,
children are followed-up (with monthly contacts) by the
research nurse for a further 6 months. This follow-up is
essential to document any recurrence of chronic cough
and any additional respiratory diagnoses. To assess
adherence to the pathway, a random sample of chil-
dren’s records (n = 10 to 20 per major participating cen-
tre: Brisbane, Sydney, Melbourne) will be examined.
Randomisation, allocation and blinding
The randomisation sequence was computer generated
and used permutated blocks (4 or 6 participants per
block). Children are randomised within two age strata
(≤6years and >6years) and 5 site strata (Brisbane, Mel-
bourne, Sydney, Canberra and Darwin). In Darwin,
children are also be stratified by Aboriginality (as
Aboriginal children in the Northern Territory are at an
increased risk of chronic respiratory disease) [17]. The
allocation sequence is concealed from all the investiga-
tors, participants and caregivers as done previously
[18]. All primary outcome data are collected by tele-
p h o n eo rb yi n t e r v i e w .T h ep a r t i c i p a n t sa r ei n f o r m e d
(at each contact) that the person they speak to on the
telephone should only be provided with direct answers
to their questions. They are also advised that they can
ring the clinical research staff directly if they need any
additional information. The research nurse responsible
for the primary outcome data collection received train-
ing on how to ensure the validity of clinical measure-
ments. Through these means, we are confident that
the person collecting the primary outcome data remain
unaware of the allocation status of the participating
child (outcome assessor blinded).
Data collection
All data are collected on standardized forms. Outcomes
(PC-QOL and PedsQL) are collected at times weeks 0
(baseline), 6, 10, 14, 26, 52 and at study endpoint. Addi-
tionally, daily cough diary scores are collected till cough
resolves. Demographic data (smoking, anthropometry,
etc) and medical details are collected at baseline.
End point
Participation is complete when the primary diagnosis is
established and cough resolved, in the presence of exit
criteria, or at 12 months from time of enrolment (what-
ever is the earliest occurrence). Exit criteria are defined
as child hospitalised for condition related to cough before
primary diagnosis is made (eg. child has hypoxaemia
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ment elsewhere for cough. Children satisfying the exit
criteria are considered ‘clinical failures’.
Definitions used for clinical management pathway
￿ Asthma: Recurrent (>2) episodes of wheeze and/or
dyspnoea that responds (within mins) to inhaled beta2
agonist, or bronchodilator resposiveness documented on
spirometry (≥12% change in FEV1 %predicted after 400
ug salbutamol).
￿ Cough resolution: Improvement of ≥75% or total
resolution according to cough diary data for ≥3c o n s e -
cutive days [19,20]. When cough diary data are unavail-
able, resolution is defined as total cessation of verbal
reporting of cough.
￿ CXR abnormality: Any abnormality (other than peri-
bronchial thickening) as interpreted by specialist
(respiratory or radiology).
￿ Primary diagnosis of aetiology of cough: Diagnosis
confirmed by subsequent specific treatment which
resulted in cough resolution within the expected time
frame of <3weeks [20,21] (see above for time frame
chosen). Diagnostic criteria are defined a-priori as
published [22].
￿ Protracted bronchitis: (a) Presence of isolated
chronic moist cough; (b) Resolution of cough with
appropriate antibiotics; and (c) absence of an alternative
cause for specific cough [20].
￿ Recurrent protracted bronchitis: ≥3 episodes per
year of protracted bronchitis.
Figure 2 Specific cough. Pathway when specific cough pointers or abnormal CXR or spirometry (if aged >3-6 yrs) are present.
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American Thoracic Society and European Respiratory
Society criteria with Australian predicted values
used [23].
￿ Secondary diagnosis: Diagnosis found on objective
tests but which: 1) specific treatment did not result in
resolution or improvement of the cough; or 2) no treat-
ment for this diagnosis was trialled and the cough
resolved with other treatment or spontaneously [22].
￿ Specific cough pointers: Presence of any of the fol-
lowing- auscultatory abnormality, classical cough char-
acteristics, cardiac abnormalities, chest pain, chest wall
deformity, daily moist or productive cough for >3
months, digital clubbing, dyspnoea (exertional or at
rest), failure to thrive, feeding difficulties (including
choking/vomiting), haemoptysis, immune deficiency,
neurodevelopmental abnormality, recurrent pneumonia,
wheeze. These pointers are explained in TSANZ posi-
tion statement [20].
￿ Spirometry abnormality: As determined by the
American Thoracic Society and European Respiratory
Society criteria with Australian predicted values used [23].
￿ Tertiary hospital management: Management that
usually requires the level of investigations at a paediatric
tertiary centre (bronchoscopy, chest HRCT scan, fluoro-
scopic swallowing screening, etc).
Description of instruments for outcome measures
￿ Parent(s) proxy cough-specific QOL (PC-QOL): A vali-
dated multi-dimensional QOL designed for parents. This
was modelled on Juniper’s paediatric asthma QOL [24].
Each of the questions has a 7 point score, from one
(worst) and 7 (best QOL). The scores to all the questions
are added and the average is taken, thus one represents
worst QOL and 7 represents best QOL [25,26].
￿ Cough diary: This validated scale is a verbal category
descriptive score ranging from 0 (no cough) to 5 (can-
not perform most usual activities due to severe cough-
ing) [27].
￿ PedsQL™ 4.0 [28]: This parent-proxy 23 item report
for children is a generic validated multi-dimensional
QOL designed for parental reports of their child’sQ O L .
It is divided into 4 age groups (2-4, 5-7, 8-12, 13-18
years).
Outcome measures
Primary outcomes for RCT: (a) proportion of children
who are cough free; and (b) difference in PC-QOL at
week 6 (with the intervention group being managed
according to the pathway for at least 4 weeks). Second-
ary outcomes: change in PedsQL scores; proportion
where a primary diagnosis was achieved; agreement of
implementation of each step of the pathway (in the
subset of children whose medical records were re-exam-
ined); clinical failure rate; diagnosis reached in number
of children within the time frame of 12 months of
enrolment; and proportion with recurrence of chronic
cough related to original primary diagnosis (ie. possible
misdiagnosis). As there are no published data on the
outcomes of chronic cough in Indigenous children,
the data from Indigenous children will be described
separately.
Sample size
To optimise the generalisability of the clinical manage-
ment pathway, all children presenting to the clinicians
over a 2 1/2 year period will be invited to participate.
We anticipate enrolling approximately 220-250 children.
This provides a sufficient power to address both primary
outcomes. For a sample size of 220, the power to detect
an improvement rate in the proportion of children
whose cough has resolved [29] at week 6 from 35% to
55% using the pathway (compared to non-use of path-
way) is 82% (significance 5%). For PC-QOL difference
between groups of 1 (a clinically significant difference)
a s s u m i n gaS Do f1 . 0 5 ,as a m p l es i z eo f5 0( 2 5p e r
group) yields a study power of 91%.
Statistical analysis and reporting
Data will be reported and presented in accordance with
the updated CONSORT criteria [30]. Children will be
analysed according to allocation status (regardless of
subsequent management). Clinical improvement will be
defined by comparing: (a) the proportions of children
who are cough free; and (b) the difference in PC-QOL
at week 6 (with the intervention group being managed
according to the pathway for at least 4 weeks). Efficacy
of the clinical management pathway will be determined
by improvements in both QOL measures and the per-
centage of children with a primary diagnosis achieved.
Reliability will be determined by agreement in the
implementation at each step of the pathway in children
who have their medical records were re-examined.
A kappa value of >0.6 will be considered acceptable for
clinical practice (as recommended) [31]. Validity of the
clinical pathway will be assessed by clinical failure rate
(defined above), diagnosis reached by 12 months, and
rates of misdiagnosis.
Unpaired and paired Student’sTt e s tw i l lb eu s e df o r
continuous data comparisons (assuming normal distri-
bution) and ANOVA utilised when >2 groups are com-
pared. If data are not normally distributed, non
parametric tests will be substituted. Chi squared tests
will be used for categorical data. The 95% confidence
intervals of all differences between the 2 study groups
will be described.
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The protocol has been granted full ethical approval from
the respective Human Research Ethics Committees of all
the participating institutions [Royal Children’sH o s p i t a l
(Brisbane), Royal Children’s Hospital (Melbourne), The
Children’s Hospital at Westmead (Sydney), Canberra
Hospital (Canberra), Royal Darwin Hospital (Darwin),
and the Menzies School of Health Research (Darwin)].
Discussion
Chronic cough is important because it causes a signifi-
cant burden of distress to parents and may reflect a ser-
ious underlying serious disorder. Determining which
children require further investigations and/or treatment
is a key management issue. High quality research is
required to determine who will benefit from which
intervention and management approaches (including
‘watchful waiting’). If use of the clinical pathway shows
a clinically important benefit, this study will represent a
substantial advance in the evidence on the management
of chronic cough in children. Further, the results will
influence clinical policy and form the basis of an
updated clinical practice guideline. A standardised clini-
cal management pathway has the potential to reduce the
morbidity of chronic cough, unnecessary costs, and
adverse events associated with medication use. As
chronic lung disease often presents with cough, this
pathway may also ensure earlier detection of serious
respiratory problems.
The rationale for the clinical pathway being studied and
study outcome measures
Our clinical management pathway is based on:
￿ Systematic evaluation of the evidence with low sus-
ceptibility to bias updated from previous publications
(in particular relevant Cochrane Reviews) [22]
￿ Definitions and key management approaches used in
the Thoracic Society of Australia and New Zealand
Position Statement [20].
￿ The findings of previous research on cough in chil-
dren where we have shown that dry cough is more likely
to resolve naturally [19].
￿ W h e r en oe v i d e n c ee x i s t s ,m a n a g e m e n ti sb a s e do n
clinical experience (approximately 250 doctor-years in
total).
Objective cough monitoring is the gold standard for
cough studies [27]. However in a clinical multi-centre
study, cough monitors are not feasible. It is also argu-
able that QOL measures are more clinically relevant
[32]. Thus we have chosen a parent cough-specific QOL
(PC-QOL) [25]. Since the presence of cough influences
QOL [33], the time taken for cough resolution is also a
clinically important outcome.
Limitations of our study
In addition to the lack of an objective measure of cough
as an outcome measure, our study could not be per-
formed as a double blinded study. Ideally, the RCT
should involve the use vs. non-use of the clinical path-
way and assess both short-term and long-term out-
comes. However, our studies over the last decade have
already influenced practice. Most specialists would not
feel comfortable withholding investigation and treatment
for a prolonged period. We have therefore designed a
RCT to assess short-term outcomes only (at 6 weeks
after initial referral). This is acceptable given the usual
waiting time to see a specialist. Importantly, our design
also allows us to assess short-term harm that might be
associated with early referral (such as over-investigation
and treatment of a spontaneously resolving illness).
In summary, this will be the first multicentre study
(conducted in 5 major Australian cities) to examine the
effectiveness of an evidence-based clinical pathway for
the management of chronic cough in children.
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